About this document
DHG Investment Analysis Report by Thong Nguyen is a document available to read on EtoBox.
The document recommends buying shares of Hau Giang Pharmaceutical JSC (DHG), a Vietnamese pharmaceutical manufacturer. DHG has strong fundamentals including projected revenue growth of 17% annually through 2017, supported by market growth and new production capacity. The target share price of VND78,034 by end of 2013 represents a 19.1% upside from the current price. Risks include construction delays, currency fluctuations, and increased competition, but DHG
- Author
- Thong Nguyen
- Language
- EN